Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrabotulinumtoxinA-xvfs vs OnabotulinumtoxinA for Forehead Rhytides
NCT05807412Phase 1Completed
- Sponsor
- Lupo Center for Aesthetic and General Dermatology
- Start
- May 2023
- Primary completion
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in forehead rhytides (2 arms), sponsored by Lupo Center for Aesthetic and General Dermatology. Primary endpoint: Surface area of rhytid diminution at 14 days. Started May 2023; status: completed.
02
Conditions
forehead rhytides
Beyond the preview
Go deeper on NCT05807412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05807412.